MRP/ERP systems connect demand forecasting, BOM explosion, supplier scheduling, inventory, lot/serial tracking, and quality holds. In regulated environments they require formal computer system validation. Validation follows a risk-based approach, and FDA's 2025 Computer Software Assurance guidance for production and quality system software encourages focusing testing on features that affect product quality. ERP systems that hold quality records need Part 11 controls such as audit trails and electronic signatures. Lot holds and quarantine status in ERP help prevent release of nonconforming product.

Why it matters

ERP changes (upgrades, configurations) are a frequent source of unexpected QMS impact - change control needs to include the ERP layer explicitly.

Common pitfalls

•A common pitfall is treating an ERP system solely as an IT tool, overlooking its critical role in controlling production and quality processes.
•Failing to involve quality assurance personnel in all stages of ERP system validation and change control can lead to non-compliant operations.
•Not adequately documenting the validation of each ERP module or configuration change can result in audit findings.
•Underestimating the impact of ERP system upgrades on existing validated processes and their associated risks is a frequent mistake.
•Over-reliance on vendor validation data without performing adequate in-house verification specific to the MedTech manufacturer's intended use is a significant oversight.

Sources

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.